These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27233365)

  • 1. Dengue encephalitis-associated immunopathology in the mouse model: Implications for vaccine developers and antigens inducer of cellular immune response.
    Marcos E; Lazo L; Gil L; Izquierdo A; Suzarte E; Valdés I; Blanco A; Ancizar J; Alba JS; Pérez Yde L; Cobas K; Romero Y; Guillén G; Guzmán MG; Hermida L
    Immunol Lett; 2016 Aug; 176():51-6. PubMed ID: 27233365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
    Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
    Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
    Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses.
    Valdés I; Marcos E; Suzarte E; Pérez Y; Brown E; Lazo L; Cobas K; Yaugel M; Rodríguez Y; Gil L; Guillén G; Hermida L
    Arch Virol; 2017 Aug; 162(8):2247-2256. PubMed ID: 28393307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
    De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
    Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.
    Züst R; Toh YX; Valdés I; Cerny D; Heinrich J; Hermida L; Marcos E; Guillén G; Kalinke U; Shi PY; Fink K
    J Virol; 2014 Jul; 88(13):7276-85. PubMed ID: 24741106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a Candidate DNA Vaccine Based on the prM/E Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain.
    Putri DH; Sudiro TM; Yunita R; Jaya UA; Dewi BE; Sjatha F; Konishi E; Hotta H; Sudarmono P
    Jpn J Infect Dis; 2015; 68(5):357-63. PubMed ID: 25766602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.
    Gil L; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Marcos E; Suzarte E; Kariuki T; Guzmán G; Guillén G; Hermida L
    Virology; 2014 May; 456-457():70-6. PubMed ID: 24889226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice.
    Gil L; López C; Lazo L; Valdés I; Marcos E; Alonso R; Gambe A; Martín J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2009 Oct; 21(10):1175-83. PubMed ID: 19692540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
    Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
    Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in immunocompetent mice.
    Amorim JH; Pereira Bizerra RS; dos Santos Alves RP; Sbrogio-Almeida ME; Levi JE; Capurro ML; de Souza Ferreira LC
    PLoS One; 2012; 7(9):e44984. PubMed ID: 23028722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates?
    Valdés I; Gil L; Lazo L; Marcos E; Martín J; Suzarte E; Castro J; Romero Y; Guillén G; Hermida L
    Arch Virol; 2016 Feb; 161(2):465-70. PubMed ID: 26590068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies are not required to a protective immune response against dengue virus elicited in a mouse encephalitis model.
    Amorim JH; dos Santos Alves RP; Bizerra R; Araújo Pereira S; Ramos Pereira L; Nascimento Fabris DL; Santos RA; Romano CM; de Souza Ferreira LC
    Virology; 2016 Jan; 487():41-9. PubMed ID: 26496698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
    Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
    Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
    Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
    J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.
    Holman DH; Wang D; Raviprakash K; Raja NU; Luo M; Zhang J; Porter KR; Dong JY
    Clin Vaccine Immunol; 2007 Feb; 14(2):182-9. PubMed ID: 17192403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
    Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
    Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.